Max Healthcare has partnered with Google to allow patients to book hospital appointments directly from Google Search and Maps, making access to verified care faster, simpler, and more reliable across India.
Entod Pharmaceuticals has developed the world's first losartan eye drops to treat corneal scarring, a major cause of vision loss. The innovation marks a global milestone in ophthalmic drug formulation.
Abbott has entered into a strategic collaboration with AtaCor Medical to develop an investigational extravascular implantable cardioverter defibrillator (EV-ICD) system, aimed at improving the safety and effectiveness of therapy for patien...
Illumina, Inc. has announced the launch of the Illumina Billion Cell Atlas, a large-scale genomic dataset intended to strengthen the scientific foundation of drug discovery and biomedical research. The announcement was made from San Diego on Thurs...
Boehringer Ingelheim has initiated a phase IIa clinical trial to evaluate BI 765423, a monoclonal antibody targeting interleukin-11 (IL-11), for the treatment of idiopathic pulmonary fibrosis (IPF). The study is part of the company’s ongoing resea...
Zydus Lifesciences has received USFDA approval for its generic Eltrombopag tablets, strengthening its U.S. generics portfolio and opening access to a blood disorder drug with strong commercial potential.
As health-tech startups and pharmaceutical innovators drive rapid adoption of injectable weight-loss drugs, new UK research has raised questions about their durability as long-term obesity solutions. While medications such as semaglutide (Wegovy...
Venus Remedies has received regulatory approval in Indonesia for ceftazidime+avibactam, enabling the country’s first generic launch and marking the company’s entry into the anti-infective segment in the key ASEAN market.
Bionpharma has received US FDA approval for its generic Etravirine tablets, developed using STEERLife’s FragMelt platform. This milestone marks a breakthrough in pharmaceutical manufacturing, offering a cost-effective HIV treatment option.
Dr. Reddy's Laboratories has introduced the OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. market, offering relief from itchy eyes due to common allergens. This first-to-market launch reinforces the company's growing presence
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")